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Abstract
Background: Better and safer antidotes against cyanide poisoning are needed. Prior study has shown a favorable
effect of isosorbide dinitrate (ISDN) on the survival of cyanide-poisoned rabbits when administered as early as
1 min after poisoning. The aim of the current study was to further evaluate the efficacy of intravenous ISDN
administered in clinically relevant timing for first responders.
Methods: A comparative animal study using 24 rabbits in 4 randomized study groups was performed. Animals
were poisoned with intravenous potassium cyanide (1 mg/kg). Animals in Group 1 served as controls and
received no treatment. Groups 2–4 animals were treated intravenously with ISDN (50 μg/kg) after poisoning;
one group after 3 min, another group after 5 min and the last after 7 min. Animals were observed for 30 min
after poisoning. The study endpoints included survival rate, clinical status, blood pressure, pulse per minute,
blood lactate and pH.
Results: Five of 6 animals (83.3%) from every treatment group survived the whole observation period while
all control untreated animals died. All the rabbits collapsed immediately after exposure, showing rapidly
deteriorated vital signs with lactic metabolic acidosis (peak blood lactate levels of 18.1 to 19.0 mmol/L on
average at 10 min post exposure). Vital signs, clinical scores, and blood gases of treated rabbits gradually
improved.
Conclusion: Poisoned rabbits showed improved short-term survival following the administration of ISDN up
to 7 min after lethal cyanide poisoning of. We see a potential for ISDN as an antidote against cyanide
poisoning.
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Background
The toxic chemical cyanide is frequently used in dif-
ferent industries [1, 2]. Cyanide poisoning poses an
imminent threat in various scenarios, both intentional
and accidental [1, 3, 4]. Currently used antidotes have
several major limitations. The expensive Hydroxoco-
balamin exerts its effects when given intravenously,
and within 10 to 15 min [5]. Another intravenously
administered antidote is sodium thiosulfate, which
also acts as a relatively slow antidote [6]. Nitrites
have significant adverse reactions such as hypotension
and profound dose-dependent methemoglobinemia.
They also have relative contraindications in certain
scenarios and populations [3, 6]. In a similar way,
dicobalt edetate is given intravenously and has several
safety issues [1, 6].
In a previous study we demonstrated that administra-
tion of intravenous isosorbide dinitrate (ISDN) within
1 min after lethal cyanide poisoning of rabbits improved
their survival with full recovery of blood gases, vital
signs and clinical scores [7].
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ISDN, is a nitrate used pharmacologically as a vaso-
dilator for angina (heart-related chest pain), congestive
heart failure, and esophageal spasms [8].
The aim of the current work is to test whether the effi-
cacy of intravenous ISDN depends on the timing from
poisoning to therapy.
Methods
We have conducted a clinically relevant animal study
using a methodology previously reported [7]. Twenty
four rabbits were studied, divided into 4 study groups.
Group 1 animals were not treated after poisoning and
served as controls. The animals of groups 2–4 were
treated intravenously with ISDN (50 μg/kg) after poison-
ing; group 2 after 3 min, group 3 after 5 min and the
group 4 after 7 min. These doses are weight-equivalent
to human doses. The study endpoints included survival
rate, clinical status (presented by a score that was devel-
oped for our previously reported study), pulse per mi-
nute, BP (blood pressure), blood lactate, and pH. The
observation time was up to ½ an hour. Prior to the start
of each research day the poison solution and the medi-
cation were specially prepared in a method previously
reported [7]. Appropriate vascular accesses were pre-
pared in the rabbit ear. Arterial blood probe was at-
tached to monitor the vital signs. This monitoring
system was successfully used in our previously reported
study [7].
The calculated cyanide poison dose was intravenously
injected. The ISDN was intravenously administered 3,
5 or 7 min after poisoning (depending on the study
group). During the continuous observation, outcomes
were recorded in time points set in advance; vital
signs every minute, clinical score at 0, 1, 2, 3, 4, 5, 7,
10, 15, 30 min, and blood sample at 0, 2, 5,10, 15,
30 min. The clinical score included 6° from death (0)
to fully alert and moving (5). Blood sampling and la-
boratory analysis was completed in a previously re-
ported method [7].
Comprehensive data analysis was conducted using
SPSS Statistics version 22, IBM®.
Results
Five of 6 rabbits (83.3%) from every treatment group
survived the whole 30 min observation period. All un-
treated animals died. The single animal per treatment
group that did not survive died in the time range of 8 to
13 min after poisoning; the untreated control animals
died in a median time to death of 8 min (range 2 to
15 min). All rabbits collapsed within 1 min of exposure,
with the clinical score falling sharply from 5 to 1. All
rabbits showed generalized tonic-clonic convulsions,
most probably seizures, within 25 to 40 s of exposure;
clinical status then deteriorated into complete unrespon-
siveness. The animals treated 3 min after poisoning had
a trend for better clinical scores when compared to ani-
mals receiving the treatment later, from 4 min after ex-
posure and until the end of observation. This was not
statistically significant when evaluated with One-Way
ANOVA test. Time vs. average clinical scores are shown
in Fig. 1.
We found a considerable drop in pulse post exposure
from average pulse rates of 240–272 per min pre-
exposure to 66–104 per min after 1 min. Mean BP in-
creased from average values of 67–74 mmHg before
poisoning to 84–111 mmHg 1 min after intoxication.
Steady improvement of BP and pulse to baseline levels
was found in all treated rabbits, while several variations
were seen between groups. Pulse values at 4 to 8 min
post intoxication were significantly higher in the 3 min
group compared to the other groups (p < 0.05, One-Way
ANOVA). Average mean BP and pulse data are pre-
sented in Figs. 2 and 3.
Shortly after poisoning, blood pH increased, represent-
ing a self-limited phase of hyperventilation, and then
fallen to profound acidosis. Steady improvement was ob-
served in all treated rabbits, yet baseline pH levels were





















Fig. 1 Mean clinical scores (± SD)
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Animals treated 3 min post exposure had significantly
higher and closer to normal range pH values at the 15
and 30 min after poisoning time points (p = 0.012 and
p = 0.038, respectively, One-Way ANOVA). Results of
blood pH are shown in Fig. 4.
We found a gradual increase in lactate levels, peaked
10 min after poisoning in all groups. A slow return to-
wards baseline levels was found in all treated rabbits but it
did not return to baseline until the end of the observation
period. Lactate levels were significantly lower and closer
to normal range in the 3 min treatment group compared
to the other later treated groups at 30 min post poisoning
(averages 13.5 vs. 17.3 and 18 mmol/L, p = 0.04, One-Way
ANOVA). Average lactate results are presented in Fig. 5.
Discussion
The study results demonstrate clear effectiveness of
intravenous ISDN administered up to 7 min after lethal
cyanide poisoning in increasing the short-term survival
of poisoned rabbits. This observation strengthens previ-
ous study results that showed survival improvement
with ISDN given 1 min after cyanide poisoning in
rabbits [7]. The importance and contribution of the
current study is the evidence it provides for ISDN clin-
ical effectiveness in a realistic time frame for first re-
sponders (estimated to be several minutes) and its
relevance as an antidote for cyanide. ISDN effectiveness
was demonstrated in clinically relevant doses (50 μg/kg),
supporting its role as a potential medical countermeas-
ure in emergency clinical settings.
The vital signs (both pulse and BP) and clinical scores
of the treated rabbits improved steadily after receiving
the drug while untreated animals deteriorated until
death. Earlier treatment (3 min after poisoning) im-
proved relatively faster the clinical status of the animals




















































Fig. 3 Mean blood pressure (mmHg ± SD)
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between the 3 min group and the other two treatment
groups was calculated for the pulse values at 4 to 8 min
after poisoning; this may be an evidence for the super-
iority of early treatment. Nevertheless, there were no sta-
tistically significant differences between the treatment
groups in any of the other clinical endpoints including
clinical scores, BP values and pulse rates beyond 8 min
post poisoning. This represents meaningful and benefi-
cial effects of ISDN administration up to 7 min post poi-
soning, not only on mere survival but also on clinical
parameters.
The recovery of blood lactate and pH levels in the
treated rabbits was less obvious than the improvement
of the clinical endpoints but still evident. Baseline values
were not achieved up to the end of the observation
period. It seems that metabolic improvement is lagging
after the clinical course. Perhaps a longer duration of
observation will demonstrate full improvement of pH
and lactate to normal range. Significant differences in
pH (at 15 and 30 min post poisoning) and lactate (at
30 min post poisoning) levels were observed between
the earlier treated animals to the other two treatment
groups; early treatment is superior in improving lactic
metabolic acidosis after cyanide poisoning. Yet, even
later treatment of up to 7 min after poisoning resulted
in the improvement of acidosis.
The presented animal model correlates well with a
human poisoning. The main mechanism of cyanide poi-
soning in humans and other mammals include the inhib-
ition of cytochrome oxidase C and the impairment of
the aerobic metabolism in the mitochondria [1]. Cyanide
toxicity occurs because this compound strongly binds to
metals, inactivating metalloenzymes such as cytochrome
c oxidase [2]. cyanide causes apoptotic cell death that is
caspase-dependent and associated with mitochondrial
membrane depolarization and cytochrome c release [9].
Lethal Cyanide poisoning exerts a distinctive clinical
course [7, 10]. This was clearly demonstrated in the
current study. Exposure to cyanide leads to a drastic ini-
tial elevation of BP, probably due to vasoconstriction.
This sharp increase in afterload can increase the oxygen
demand and the heart’s load, thus impairing cardiac
output. This may lead to myocardial ischemia and
bradycardia.
Another prominent clinical observation was the early
development of seizures. Cyanide, through disruption of
brain glutamatergic transmission, induces apnea and sei-
zures [11]. In rats, within 30 s after exposure to cyanide,
glutamate levels increase in several brain regions [12].
Inward currents produced by the NMDA receptor which
can potentiate glutamatergic activity are also enhanced
by cyanide [13].
Nitrates are rapidly reduced to nitric oxide (NO) in
blood and in tissues, in a NO synthase-independent
pathway [14, 15]. The production of NO is increased
gradually as oxygen tensions falls [16, 17]. NO leads to
vasodilatation, that can improve vascular bed ischemia,
via the relaxation of muscle cells [18, 19]. Vasodilatation
reduces the afterload (arterial pressure) and the preload
(the pressure of the blood returning to the heart) [20].
NO may also increase the oxygen supply to the heart,
through reduction of coronary spasm. The administra-
tion of nitrates as ISDN in acute coronary events, ame-
liorates myocardial ischemia by improving coronary flow
and decreasing cardiac workload [21, 22]. Phenoxyben-
zamine and chlorpromazine — other vasodilators—can
also improve survival after exposure to cyanide [23–25].
NO-induced vasodilatation seems to have a beneficial
role in cyanide intoxication.
The severity of the lactic acidosis as expressed by the
blood lactate and pH levels was not different between
treated and untreated animals in the study while a clear
difference was observed regarding the vital signs’ dy-
namics. It seems that the circulatory improvement of
the treated animals was better predictive and correlated
with their survival compared with their metabolic status.




























Fig. 5 Mean blood lactate (mmol/L ± SD)
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This supports the suggested mechanism of action of
ISDN in cyanide exposure, improved circulation.
NO has direct antagonistic effect on cyanide in the
mitochondrial electron transport chain, as it competes
with it for binding to cytochrome c oxidase [26, 27].
Leavesley et al. demonstrated in an animal model that
addition of exogenous NO attenuated cyanide inhibition
of cytochrome c oxidase [27]. The same was observed
when sodium nitrite was used as the source of NO that
interacted directly with the binding of potassium cyanide
with cytochrome c oxidase to reverse toxicity [28]. Also,
it seems as if NO protects enzymatic systems from cyan-
ide inactivation via a mechanism involving the formation
of an enzyme-nitrosyl cyanide complex [29].
Brain NMDA-receptor hyperactivity reduction is an-
other potential mechanism of NO protection in cyanide
poisoning. NO+ ion protects from excessive stimulation
of the NMDA receptor by binding to its redox regula-
tory site [30]. This may attenuate repeated seizures as
seen in the current study after ISDN administration.
The direct and independent antidotal activity of NO in
cyanide poisoning is probably a more important and faster
mechanism of nitrites and nitrates as cyanide antidotes
than methemoglobin formation. Several animal and hu-
man studies showed that nitrites (sodium and amyl) im-
proved survival in cyanide poisoning without forming
significant levels of methemoglobin [7, 11, 31–33].
Production rate of methemoglobin by nitrites is rela-
tively slow in humans [34]. The reported early recov-
ery of severe cyanide poisoned victims following nitrite
treatment is too fast to be explained by methemoglobin
formation [31, 35, 36].
While nitrates in therapeutic doses do not form
methemoglobin, they were not considered relevant for
cyanide poisoning. However, as it is shown and proven
that NO antagonism is a principle mechanism in cyanide
treatment, nitrates should be incorporated in the proto-
cols implemented in cyanide exposure and poisoning
particularly in the field setup or in mass casualty
incidents.
Nitrates present several advantages over currently used
antidotes. Nitrates are an approved, safe, and low cost
treatment, easily available and widely used; particularly
in cardiac patients [37–40]. There are various rapidly
absorbed formulations with easy and effective applica-
tion in pre-hospital setups, even by laymen [38]. Nitrates
have no significant interactions with other cyanide anti-
dotes or resuscitation medications [37, 38].
The study has several limitations. It is a limited num-
ber rabbit study with a short-term follow up period. Ex-
posure to cyanide was achieved in the intravenous route,
which is not the usual human exposure route. The in-
vestigators were not blinded to the control and treat-
ment groups.
Conclusion
Intravenous administration of ISDN up to 7 min after
minimally lethal cyanide poisoning improved the short-
term survival of poisoned rabbits. ISDN shows marked
potential as an antidote for cyanide poisoning. Further
research is needed to evaluate the effectiveness of ni-
trates in other modes of delivery, different animal
models and poisoning scenarios.
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